Skip to main content

Advertisement

SpringerLink
Log in

Incorporating Novel Agents in the Management of Elderly Myeloma Patients

  • Multiple Myeloma (R Niesvizky, Section Editor)
  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

In recent years, the treatment of multiple myeloma has undergone significant changes. The availability of novel agents bortezomib, thalidomide and lenalidomide considerably improved the outcome of patients. The advantages related to the use of novel agents have been shown in various studies in patients eligible and ineligible for transplant. In elderly patients, novel agents have also revolutionized the treatment paradigm and have replaced the traditional melphalan-prednisone regimen. A sequential approach consisting of an induction regimen associated with a high rate of complete response, followed by consolidation/maintenance therapy, induces a profound cytoreduction and delays relapse, thus improving survival. Patients older than 75 years or who are otherwise vulnerable are more susceptible to adverse events. In this setting, less toxic regimens and appropriate dose-reductions should be adopted. This article provides an overview of the main trials for transplant-ineligible multiple myeloma patients. Recommendations on how to manage unfit patients and treatment-related toxicities are also provided.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046–60.

    Article  PubMed  CAS  Google Scholar 

  2. • Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012;12:335–48. This paper reports an interesting theory: myeloma is a heterogeneous disease characterized by different sub-clones that determine the disease course and the possible response to drugs.

    Article  PubMed  CAS  Google Scholar 

  3. Walker BA, Wardell CP, Melchor L, et al. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia 2013, in press.

  4. Ludwig H, Avet-Loiseau H, Bladé J, et al. European perspective on multiple myeloma treatment strategies: update following recent congresses. Oncologist. 2012;17:592–606.

    Article  PubMed  CAS  Google Scholar 

  5. Lonial S, Miguel JF. Induction therapy for newly diagnosed multiple myeloma. J Natl Compr Canc Netw. 2013;11:19–28.

    PubMed  CAS  Google Scholar 

  6. Palumbo A, Mina R. Part II: role of maintenance therapy in transplant-ineligible patients. J Natl Compr Canc Netw. 2013;11:43–9.

    PubMed  CAS  Google Scholar 

  7. Howlade N, Noone A, Krapcho M, et al. Seer Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations). Bethesda, MD: National Cancer Institute; 2012 [http://seer.cancer.gov/csr/1975_2009_pops09/, based on November 2011 seer data submission, posted to the seer web site].

  8. Beker N. Epidemiology of multiple myeloma. Recent Results Cancer Res. 2011;183:25–35.

    Article  Google Scholar 

  9. Landgren Q, Weiss BM. Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis. Leukemia. 2009;23:1691–7.

    Article  PubMed  CAS  Google Scholar 

  10. Alavanja MC, Ross MK, Bonner MR. Increased cancer burden among pesticide applicators and others due to pesticide exposure. CA Cancer J Clin. 2013;63:120–42.

    Article  PubMed  Google Scholar 

  11. Greenberg AJ, Rajkumar SV, Vachon CM. Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics. Blood. 2012;119:5359–66.

    Article  PubMed  CAS  Google Scholar 

  12. • Palumbo A, Bringhen S, Ludwig H, et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of European Myeloma Network (EMN). Blood. 2011;118:4519–29. An important and recent EMN report on frail patients.

    Article  PubMed  CAS  Google Scholar 

  13. Palumbo A, Sezer O, Kyle R, et al. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia. 2009;23:1716–30.

    Article  PubMed  CAS  Google Scholar 

  14. Palumbo A, Bringhen S, Petrucci MT, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood. 2004;104:3052–7.

    Article  PubMed  CAS  Google Scholar 

  15. Palumbo A, Gay F, Falco P, et al. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. J Clin Oncol. 2010;28:800–7.

    Article  PubMed  CAS  Google Scholar 

  16. Straka C, Schafer-Eckart K, Bassermann F, et al. Prospective randomized trial of Len/Dex induction followed by tandem Mel 140 with autologous blood stem cell transplantation and Len maintenance versus continued therapy with Len/Dex in myeloma patients age 60–75 years: protocol-defined safety analysis after 100 patients. Abstract presented at the 54th American Society of Hematology conference. Atlanta, Georgia; December 8-11, 2012.

  17. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomized controlled trial. Lancet. 2006;367:825–31.

    Article  PubMed  CAS  Google Scholar 

  18. Palumbo A, Bringhen S, Liberati AM, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood. 2008;112:107–14.

    Article  Google Scholar 

  19. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007;370:1209–18.

    Article  PubMed  CAS  Google Scholar 

  20. Wijermans P, Schaafsma M, Termorshuizen F, et al. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. J Clin Oncol. 2010;28:3160–6.

    Article  PubMed  CAS  Google Scholar 

  21. Hulin C, Facon T, Rodon P, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol. 2009;27:64–70.

    Article  Google Scholar 

  22. Waage A, Gimsing P, Fayers P, et al. Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood. 2010;116:1405–12.

    Article  PubMed  CAS  Google Scholar 

  23. Beksac M, Haznedar R, Firatli-Tuglular T, et al. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. Eur J Haematol. 2011;86:16–22.

    Article  PubMed  CAS  Google Scholar 

  24. • Fayers PM, Palumbo A, Hulin C, et al. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood. 2011;118:1239–47. An interesting meta-analysis combining patient data from 6 randomized trials with MPT.

    Article  PubMed  CAS  Google Scholar 

  25. Palumbo A, Waage A, Hulin C, et al. Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials. Haematologica. 2013;98:87–94.

    Article  PubMed  CAS  Google Scholar 

  26. Morgan GJ, Davies FE, Gregory WM, et al. Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood. 2011;118:1231–8.

    Article  PubMed  CAS  Google Scholar 

  27. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906–17.

    Article  PubMed  CAS  Google Scholar 

  28. Mateos MV, Richardson PG, Schlag R, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol. 2010;28:2259–66.

    Article  PubMed  CAS  Google Scholar 

  29. • San Miguel JF, Schlag R, Khuageva NK, et al. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated myeloma. J Clin Oncol. 2013;31:448–55. A recent update of the VISTA study confirming the benefit of VMP over MP.

    Article  PubMed  CAS  Google Scholar 

  30. Mateos MV, Oriol A, Martínez-López J, et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol. 2010;11:934–41.

    Article  PubMed  CAS  Google Scholar 

  31. Palumbo A, Bringhen S, Rossi D, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol. 2010;28:5101–9.

    Article  PubMed  CAS  Google Scholar 

  32. • Palumbo A, Bringhen S, Rossi D, et al. Overall survival benefit for bortezomib–melphalan–prednisone–thalidomide followed by maintenance with bortezomib–thalidomide (VMPT–VT) versus bortezomib–melphalan–prednisone (VMP) in newly diagnosed multiple myeloma patients. Abstract presented at the 54th American Society of Hematology conference. Atlanta, Georgia; December 8-11, 2012. The study with the highest rate of CR. Median overall survival was not reached yet, and it may be quite high.

  33. Falco P, Cavallo F, Larocca A, et al. Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients. Leukemia. 2013;27:695–701.

    Article  PubMed  CAS  Google Scholar 

  34. • Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;336:1759–69. A recent study confirming the benefit of lenalidomide maintenance after MPR treatment.

    Article  Google Scholar 

  35. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11:29–37.

    Article  PubMed  CAS  Google Scholar 

  36. Mateos MV, Oriol A, Martínez-López J, et al. Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. Blood. 2012;120:2581–8.

    Article  PubMed  CAS  Google Scholar 

  37. Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood. 2010;116:4745–53.

    Article  PubMed  CAS  Google Scholar 

  38. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12:431–40.

    Article  PubMed  Google Scholar 

  39. Richardson PG, Sonneveld P, Schuster MW, et al. Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487–98.

    Article  PubMed  CAS  Google Scholar 

  40. Richardson PG, Sonneveld P, Schuster MW, et al. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol. 2007;137:429–35.

    Article  PubMed  CAS  Google Scholar 

  41. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357:2123–32.

    Article  PubMed  CAS  Google Scholar 

  42. Weber DM, Chen C, Niesvisky R, et al. lenalidomide plus dexamethasone for relapsed myeloma in North America. N Engl J Med. 2007;357:2133–42.

    Article  PubMed  CAS  Google Scholar 

  43. Touzeau C, Blin N, Clavert A, et al. Efficacy of lenalidomide and dexamethasone in patients older than 75 years with relapsed multiple myeloma. Leuk Lymphoma. 2012;53:1318–20.

    Article  PubMed  CAS  Google Scholar 

  44. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007;25:3892–901.

    Article  PubMed  CAS  Google Scholar 

  45. Guglielmelli T, Bringhen S, Rrodhe S. Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients. patients. Eur J Cancer. 2011;47:814–8.

    Article  PubMed  CAS  Google Scholar 

  46. • Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012;120:2817–25. Recent protocol showing promising results with carfilzomib.

    Article  PubMed  CAS  Google Scholar 

  47. • Vij R, Wang M, Kaufman JL, et al. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood. 2012;119:5661–70. Recent protocol showing promising results with carfilzomib.

    Article  PubMed  Google Scholar 

  48. • MA Dimopoulos, MD1, MQ Lacy, et al. Pomalidomide in Combination with Low-Dose Dexamethasone: Demonstrates a Significant Progression Free Survival and Overall Survival Advantage, in Relapsed/Refractory MM: A Phase 3, Multicenter, Randomized, Open-Label Study. Abstract presented at the 54th American Society of Hematology conference. Atlanta, Georgia; December 8-11, 2012. Recent study confirming the benefit of salvage therapy with pomalidomide after lenalidomide and bortezomib.

  49. Gay F, Palumbo A. Management of older patients with multiple myeloma. Blood Rev. 2011;25:65–73.

    Article  PubMed  CAS  Google Scholar 

  50. Richardson PG, Sonneveld P, Schuster MW, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol. 2009;144:895–903.

    Article  PubMed  CAS  Google Scholar 

  51. Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22:414–23.

    Article  PubMed  CAS  Google Scholar 

  52. Dimopoulos MA, Terpos E, Chana-Khan A, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol. 2010;28:4976–84.

    Article  PubMed  Google Scholar 

  53. Terpos E, Sezer O, Crocher PI, et al. The use of biphosphonates in multiple myeloma: recommendation of an expert panel on behalf of the International Myeloma Working Group. J Clin Oncol. 2009;20:1303–17.

    CAS  Google Scholar 

  54. Bringhen S, Mateos MV, Zweegman S, et al. Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica. 2013;98:980–7.

    Article  PubMed  Google Scholar 

Download references

Acknowledgment

The authors thank editorial assistant Giorgio Schirripa.

Compliance with Ethics Guidelines

ᅟ

Conflict of Interest

Tommasina Guglielmelli and Antonio Palumbo declare no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Unit of Hematology, “S. Luigi Gonzaga” Hospital, Orbassano, Italy

    Tommasina Guglielmelli

  2. Myeloma Unit, Division of Hematology, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy

    Antonio Palumbo

Authors
  1. Tommasina Guglielmelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antonio Palumbo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Antonio Palumbo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Guglielmelli, T., Palumbo, A. Incorporating Novel Agents in the Management of Elderly Myeloma Patients. Curr Hematol Malig Rep 8, 261–269 (2013). https://doi.org/10.1007/s11899-013-0177-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-013-0177-y

Keywords

Search

Navigation